The Hong Kong-listed biotech granted Pharmanovia exclusive rights across 66 countries, extending the ovarian cancer drug’s reach beyond China as European approval is expected in the second half of 2026.
IMPACT Therapeutics (07630.HK) has signed an exclusive partnership with Pharmanovia covering Senaparib across 66 countries in Europe, the Middle East, North Africa, Australia and New Zealand, marking the company’s first step to commercialize the drug outside China. Under the agreement, Pharmanovia receives exclusive rights to manufacture, develop and commercialize Senaparib for maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer in the covered markets. IMPACT said it is eligible to receive up to EUR423.5 million in total consideration, including an upfront payment, near-term regulatory milestones and commercial milestone payments tied to sales thresholds, plus tiered royalties up to the mid-twenties on net product sales. The company said the deal expands Senaparib’s global reach to 66 countries. The territory includes all 27 European Union member states, as well as the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and countries in the Middle East and North Africa. Senaparib, a PARP1/2 inhibitor developed by IMPACT, was approved by China’s National Medical Products Administration in January 2025 as a first-line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who achieved a complete or partial response to platinum-based chemotherapy. It was later added to China’s National Reimbursement Drug List in December 2025. In Europe, the drug’s Marketing Authorisation Application was formally accepted by the European Medicines Agency in August 2025, with approval expected in the second half of 2026.